

# The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology

## Authors

---

Anna J.T. Smit,<sup>1\*</sup> Niek G. van der Maas,<sup>1\*</sup> Bronno van der Holt,<sup>1,2</sup> Yvette van Norden,<sup>1,2</sup> Erik van Werkhoven,<sup>1,2</sup> Annette Juul Vangsted,<sup>3</sup> Paula F. Ypma,<sup>4</sup> Heleen A. Visser-Wisselaar,<sup>2</sup> Rossella Troia,<sup>5</sup> Mario Boccadoro,<sup>5</sup> Bob Löwenberg,<sup>1</sup> Jeroen J. W. M. Janssen,<sup>6</sup> Gert J. Ossenkoppele,<sup>7</sup> Fredrik Schjesvold,<sup>8</sup> Pieter Sonneveld,<sup>1</sup> Sonja Zweegman,<sup>9</sup> Jurjen Versluis<sup>1</sup> and Jan J. Cornelissen<sup>1</sup>

<sup>1</sup>Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands; <sup>2</sup>HOVON Foundation, Rotterdam, the Netherlands; <sup>3</sup>Department of Hematology, Rigshospitalet, Copenhagen, Denmark; <sup>4</sup>Department of Hematology, HagaZiekenhuis, Den Haag, the Netherlands; <sup>5</sup>European Myeloma Network, Turin, Italy; <sup>6</sup>Department of Hematology, Radboud UMC, Nijmegen, the Netherlands; <sup>7</sup>Amsterdam UMC, location VUMC, Cancer Center Amsterdam, Amsterdam, the Netherlands; <sup>8</sup>Oslo Myeloma Center,

Department of Hematology, Oslo University Hospital, Oslo, Norway and <sup>9</sup>Department of Hematology, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam, the Netherlands

*\*AJTS and NGvDM contributed equally as first authors.*

Correspondence:

J.J. CORNELISSEN - j.cornelissen@erasmusmc.nl

<https://doi.org/10.3324/haematol.2025.288675>

Received: July 10, 2025.

Accepted: September 24, 2025.

Early view: October 2, 2025.

©2026 Ferrata Storti Foundation


Published under a CC BY-NC license 

## **SUPPLEMENTARY MATERIALS**


to

The added value of Bayesian interim analysis in randomized phase II and phase III  
clinical trials in hemato-oncology by Smit, Van Der Maas et al.


# A



# B




**C**



**Figure S1A-C. Original study design flow diagrams of the HOVON95/EMN02, HOVON87/NMSG18 and HOVON103/SAKK30/10 trials**

Abbreviations: AML: acute myeloid leukemia; CR: complete remission; HSCT: hematopoietic stem cell transplantation; MDS: myelodysplastic syndrome; NDMM: newly diagnosed multiple myeloma; WHO: World Health Organization.



**Figure S2A-C. Conventional group sequential design with non-binding two-sided hazard ratio bounds for stopping for efficacy or futility at each interim analysis of the HOVON95/EMN02, HOVON87/NMSG18 and HOVON103/SAKK30/10 trials**

Abbreviations: CR: complete remission.